Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

1263W94 [maribavir; 5,6-dichloro-2-(isopropylamino)-1,β-l-ribofuranosyl-1-H-benzimidazole] is a novel benzimidazole compound for treatment of human cytomegalovirus (HCMV) infection and disease, with potent in vitro activity against HCMV and good oral bioavailability. A phase I study was conducted to...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Lalezari, Jacob P., Aberg, Judith A., Wang, Laurene H., Wire, Mary Beth, Miner, Richard, Snowden, Wendy, Talarico, Christine L., Shaw, Shuching, Jacobson, Mark A., Drew, W. Lawrence
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2002
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC127448/
https://ncbi.nlm.nih.gov/pubmed/12183255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.46.9.2969-2976.2002
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires